{
  "docId": "019de072-0f48-75dc-8e26-6c36719c246a",
  "docSlug": "59aa3600901f9a5fdbc1ca4ce261b5cc",
  "documentTitle": "Vigil Neuroscience | IPO Presentation Deck | 54 slides",
  "authorId": "vigil-neuroscience",
  "authorName": "Vigil Neuroscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 10,
  "pageCount": 54,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide emphasizes exclusivity in the development pipeline for both modalities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0f48-75dc-8e26-6c36719c246a/10",
  "deckHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a",
  "deckJsonHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a.json",
  "deckAnchorHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.55,
        "y": 0.7
      },
      "kind": "callout",
      "text": "The ONLY TREM2 small molecule agonist in development",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02747235-3014-4732-8f07-2685157a5e78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.1,
        "y": 0.7
      },
      "kind": "callout",
      "text": "The ONLY targeted drug candidate in development for ALSP",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59665d2d-8045-463c-a2da-95a8609556a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Vigil Neuroscience",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eae4dafe-c879-4a5c-998f-1dc22c81e3bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.6,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Small Molecule TREM2 Agonist in Development for Larger Indications",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c24b03e-6bd6-4aa5-8fdb-f551dc109cd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.15,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "TREM2 mAb in Development for ALSP: VGL101",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd562232-d1d6-4b8b-aaff-bc19bd28bb0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "ALSP: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42f30028-a75f-48e0-be48-cc5a7dfbe640",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Vigil TREM2 Agonists: Differentiated Strategy and Multiple Modalities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd51ac93-93bd-4333-82c6-78eb81430dfa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "8de61beb-c317-405f-998a-6d38b255896f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents VGL101 as a potential solution for neurodegenerative diseases and provides data on its efficacy and safety.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}